IMARC Group's report titled "Insomnia Market Report by Therapy Type (Non-Pharmacological Therapy, Pharmacological Therapy), Drug Class (Antidepressants, Melatonin Antagonist, Benzodiazepines, Nonbenzodiazepines, Orexin Antagonist, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies), and Region 2024-2032". offers a comprehensive analysis of the industry, which comprises insights on the global insomnia market demand. The global market size reached US$ 5.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.6 Billion by 2032, exhibiting a growth rate (CAGR) of 2.69% during 2024-2032.

Grab a sample PDF of this report: https://www.imarcgroup.com/insomnia-market/requestsample

Factors Affecting the Growth of the Insomnia Industry:

• Increasing Aging Population:

Insomnia is becoming more common as people are aging. Older adults often experience changes in sleep patterns, including lighter sleep, more frequent awakenings during the night, and earlier wake-up times. As a result, the prevalence of insomnia tends to be higher in the elderly population compared to younger age groups. Moreover, aging is often accompanied by the onset or exacerbation of various medical conditions, such as chronic pain, arthritis, respiratory disorders, and neurological conditions like Parkinson's disease or dementia. These comorbidities can contribute to insomnia or make it more difficult to manage, leading older adults to seek treatment for their sleep problems.

• Technological Advancements:

Innovations in technology are leading to the development of digital health solutions for insomnia management. Mobile applications, wearable devices, and online platforms offer various tools and resources for tracking sleep patterns, implementing cognitive behavioral therapy for insomnia (CBT-I) techniques, and monitoring progress over time. These digital tools provide individuals with convenient and accessible options for managing their sleep disorders, thereby expanding the reach of insomnia treatments. Furthermore, advancements in telemedicine technologies allow healthcare providers to assess and monitor patients with insomnia remotely. Virtual consultations, remote monitoring tools, and telehealth platforms enable individuals to receive personalized sleep assessments, access evidence-based treatments, and receive ongoing support from healthcare professionals without the need for in-person visits.

• Rising Healthcare Expenditure:

As healthcare spending is increasing, the investment in research and development (R&D) activities in the pharmaceutical and medical industries is rising. Pharmaceutical companies and device manufacturers are allocating resources to develop new insomnia treatments, innovative therapies, and advanced diagnostic tools. This R&D investment leads to the discovery of novel drugs, formulations, and technologies for managing insomnia more effectively, thereby expanding the range of treatment options available in the market. In addition, rising healthcare expenditures often translates into the expansion and modernization of healthcare infrastructure, including hospitals, clinics, sleep centers, and outpatient facilities. The availability of state-of-the-art diagnostic equipment, sleep laboratories, and specialized sleep clinics enables healthcare providers to offer comprehensive sleep evaluation and management services to patients with insomnia.

Leading Companies Operating in the Global Insomnia Industry:

• Astellas Pharma Inc.
• Aurobindo Pharma Limited
• Biocodex
• Eisai Co. Ltd.
• Mallinckrodt Pharmaceuticals
• Merck & Co. Inc.
• Neurim Pharmaceuticals Inc.
• Pfizer Inc.
• Sanofi S.A.
• Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.)
• Takeda Pharmaceutical Company Limited
• Vanda Pharmaceuticals Inc.

Insomnia Market Report Segmentation:

By Therapy Type:

• Non-Pharmacological Therapy
  • Hypnotherapy
  • Cognitive Behavioral Therapy
  • Medical Devices
  • Others
• Pharmacological Therapy
  • Prescription Sleep Aids
  • Over-The-Counter Sleep Aids

Pharmacological therapy represents the largest segment due to the widespread availability and utilization of prescription and over-the-counter (OTC) medications for sleep disorders.

By Drug Class:

• Antidepressants
• Melatonin Antagonist
• Benzodiazepines
• Nonbenzodiazepines
• Orexin Antagonist
• Others

Benzodiazepines account for the majority of the market share owing to their long-standing history of use and established efficacy in promoting sleep.

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Based on the distribution channel, the market has been divided into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position in the insomnia market on account of advanced healthcare infrastructure and a robust network of healthcare providers specializing in sleep medicine.

Global Insomnia Market Trends:

Wearable devices equipped with sleep-tracking capabilities, such as smartwatches and fitness bands, enable individuals to monitor their sleep duration, quality, and patterns in real-time. These devices can provide valuable insights into sleep habits and identify potential sleep disturbances, empowering users to make lifestyle changes or seek professional help for their insomnia. The growing popularity and affordability of wearable sleep trackers are contributing to the increasing awareness and proactive management of sleep disorders.

Additionally, technological innovations in sleep monitoring devices, such as polysomnography (PSG) equipment and home sleep apnea testing (HSAT) devices, enable healthcare providers to accurately diagnose sleep disorders, including insomnia, in clinical and home settings. These diagnostic tools provide objective data on sleep architecture, respiratory parameters, and nocturnal behaviors, facilitating the identification of underlying sleep disturbances and informing personalized treatment approaches for insomnia patients.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163